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Abstract 
Diabetic patients frequently suffer from continuous pain that is poorly treated by currently available 
analgesics. Here we used mouse models of Type 1 and Type 2 diabetes to investigate a possible role 
for the hyperpolarization-activated cyclic nucleotide–gated 2 (HCN2) ion channels as drivers of 
diabetic pain. Blocking or genetically deleting HCN2 channels in small nociceptive neurons 
suppressed diabetes-associated mechanical allodynia and prevented neuronal activation of second-
order neurons in the spinal cord in mice. In addition, we found that intracellular cyclic adenosine 
monophosphate (cAMP), a positive HCN2 modulator, is increased in somatosensory neurons in an 
animal model of painful diabetes. We propose that the increased intracellular cAMP drives diabetes-
associated pain by facilitating HCN2 activation and consequently promoting repetitive firing in 
primary nociceptive nerve fibers.  Our results suggest that HCN2 may be an analgesic target in the 
treatment of painful diabetic neuropathy. 
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Introduction 
Diabetes causes a characteristic degeneration of peripheral sensory nerves, frequently associated 
with continuous pain. Painful diabetic neuropathy (PDN) affects approximately one in four diabetic 
patients and typically manifests itself as a range of unpleasant positive symptoms such as 
spontaneous pain, mechanical allodynia (a painful sensation caused by light touch) and paresthesias 
(tingling, shooting pain), as well as negative symptoms such as thermal hyposensitivity (1). Despite 
its high prevalence, the pathophysiology of PDN remains poorly understood. Both anatomical 
changes (demyelination, loss of epidermal nerve density) and functional changes (reduced nerve 
conduction velocity) are characteristic of PDN and of other ‘die-back’ neuropathies (1-4). The 
pathologies observed in the peripheral nervous system suggest that peripheral nerve damage is the 
driver of PDN, and that the associated ongoing pain is likely to be due to repetitive discharge of 
action potentials in nociceptive (pain-sensitive) nerve fibers (5-7). However, the molecular basis of 
peripheral nociceptor hyperexcitability remains elusive.  
Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels have recently emerged as 
crucial determinants of nociceptive excitability (reviewed in 8, 9). HCN channels are unusual in that 
they are activated by hyperpolarization in the range -60 mV to -90 mV, in contrast to all other 
voltage-activated channels which are activated by depolarization. There are four HCN isoforms 
(HCN1-4) expressed in sensory neurons. More than half of small nociceptive neurons express HCN2 
channels (10), whereas in large sensory neurons the fast HCN current (Ih) is mediated mainly by 
HCN1 (11, 12). HCN3 is widely expressed across dorsal root ganglion (DRG) neurons of all sizes (11), 
whereas HCN4, which has a key pacemaking role in the heart (13, 14), shows limited expression in 
somatosensory neurons (15, 16). Elevations of intracellular cAMP cause a strong shift in the voltage 
dependence of activation of HCN2 and HCN4 to more positive membrane voltages, causing an 
increase in the inward current carried by these channels at resting membrane voltage, whereas 
HCN1 and HCN3 are relatively insensitive to cAMP and so have less influence in modulating neuronal 
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excitability (17). In nociceptive neurons, inflammatory mediators such as prostaglandin E2 (PGE2) 
and bradykinin activate adenylate cyclase via a Gs-protein-coupled pathway, thus causing a rise in 
intracellular cAMP, HCN2 activation, and increased spontaneous firing of action potentials (10).  
A critical role for HCN2 in inflammatory pain and in the neuropathic pain caused by direct 
mechanical damage to sensory nerves has been demonstrated by the potent analgesic actions of 
specific HCN channel blockers and by targeted deletion of the Hcn2 gene in nociceptive neurons in 
mice (10). Pharmacological inhibition of Ih prevents pain in chemotherapy-induced neuropathy (18), 
which also features a ‘die-back’ denervation pattern, and circumstantial evidence has hinted at an 
involvement of unidentified HCN family members in autonomic diabetic neuropathy (19, 20).  
Here we expand our understanding of the critical role of HCN2 in chronic pain by showing that 
cAMP-mediated HCN2 activation in a mouse model of diabetic neuropathy can trigger repetitive 
activity in small nociceptive fibers, leading to central sensitization and ongoing pain. Pharmacological 
or genetic block of HCN2 activity exerts potent analgesic effects in animal models of both Type 1 and 
Type 2 diabetes. 
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Results 
Streptozotocin treatment results in symptoms indicative of painful diabetic neuropathy 
Diabetes was induced in wild-type (WT) mice by a single injection of streptozotocin (STZ). Selective 
accumulation of STZ in pancreatic islet β cells causes DNA alkylation, cell death, and consequent loss 
of insulin production, resulting in an elevation of blood glucose. Mice treated with STZ exhibited 
significantly increased blood glucose concentrations by day 7 compared to the pre-STZ baseline (Fig. 
1A; 21.9 ± 2.1 mmol/L vs 8.4 ± 0.2 mmol/L, P<0.001). STZ-treated mice remained hyperglycemic 
thereafter, whereas blood glucose concentration did not change in vehicle-treated mice (10.1 ± 0.7 
mmol/L). The small number of mice that did not exhibit hyperglycemia after STZ injection were 
excluded from analysis (see Table 1).  
We examined whether the diabetic state was accompanied by altered pain sensation, similar to that 
encountered in human PDN. Diabetic mice showed a progressive hypersensitivity in response to 
mechanical stimulation (Fig. 1B). The mechanical pain threshold was significantly lower than baseline 
at 2 weeks, as indicated by the mean force required to elicit paw withdrawal to mechanical 
stimulation (4.1 ± 0.1 g vs 3.5 ± 0.1 g, P=0.012) and continued to decrease until 8 weeks (2.3 ± 0.1 g, 
P<0.001), representing a 44% increase in mechanical pain sensitivity (Fig. 1B). Mechanical 
hypersensitivity persisted for at least 18 weeks post-STZ (2.7 ± 0.1 g, P<0.001). In contrast, 
mechanical pain thresholds of vehicle-treated mice remained at baseline levels for the duration of 
the study (Fig. 1B). Testing with a thermal heat stimulus revealed thermal hyposensitivity 6-8 weeks 
after induction of diabetes, as indicated by increased latency of paw withdrawal (6 weeks, 12.0 ± 0.6 
sec vs 9.2 ± 0.6 sec, P=0.002; 8 weeks, 12.7 ± 0.5 sec vs 9.4 ± 0.5 sec, P<0.001 compared to vehicle-
treated mice) (Fig. 1C). The dual manifestation of mechanical hypersensitivity and thermal 
hyposensitivity mirrors the clinical presentation of diabetic neuropathy in humans. Activation of 
transient receptor potential ankyrin 1 (TRPA1) by STZ may be responsible for some of the 
manifestations of pain for 10 days after administration of STZ (21), and for this reason we carried out 
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behavioral pain measurements at later time points (8-18 weeks post-STZ).  Of note, Fig. 1B and C 
include all mice that developed diabetes, but for unknown reasons only 70-90% of these mice 
developed substantial pain hypersensitivity (see Methods and Table 1).  
 
Blocking peripheral HCN channels reverses mechanical hypersensitivity  
We next investigated whether HCN function is involved in the mechanical pain hypersensitivity in 
PDN. To address this, we selected mice with the most robust pain phenotypes at 8 weeks post-STZ 
and injected them intraperitoneally with ivabradine, which inhibits all four HCN isoforms with 
approximately equal potency (22). Note that ivabradine is excluded from the CNS (18), so its actions 
can be attributed to blockade of HCN ion channels in the periphery. A single injection of 2.5 mg/kg 
ivabradine increased diabetic pain thresholds (from 2.2 ± 0.2 g after STZ to 3.1 ± 0.2 g at 30 min, 
P=0.006 and 3.2 ± 0.2 g at 60 min after ivabradine injection, P=0.002) (Fig. 1D). This effect was also 
observed with higher ivabradine doses (5 mg/kg: from 2.3 ± 0.1 g after STZ to 3.2 ± 0.5 g at 30 min 
and 3.1 ± 0.3 g at 60 min after ivabradine injection, P=0.018 and P=0.024, respectively; 10 mg/kg: 
from 2.1 ± 0.1 g after STZ to 3.1 ± 0.3 g at 30 min and 3.3 ± 0.3 g at 60 min after ivabradine injection, 
P=0.001 and P<0.001, respectively). At all doses, the ivabradine-mediated analgesic effect on pain 
threshold was significant compared to the vehicle group at 60 min after ivabradine injection (2.5 
mg/kg, P=0.014; 5 mg/kg, P=0.016; 10 mg/kg: P=0.021) and subsided after 120 min. Ivabradine had 
no effect on acute mechanical and thermal pain thresholds of control mice (Fig. 1D and fig. S1), 
confirming previous observations that HCN channels are not engaged during normal acute pain 
processing (10). In addition, thermal hypoesthesia in mice treated with STZ was unaltered by 
ivabradine (fig. S1), suggesting that thermal hyposensitivity is unrelated to changes in HCN ion 
channel function.  
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Because ivabradine did not completely restore normal pain sensitivity, we asked whether the 
analgesic effect could be enhanced by repeated administration of the drug. Two consecutive 
injections (5 mg/kg, separated by 2 hours) increased pain thresholds beyond those of a single 
administration, and a third injection completely restored thresholds to pre-diabetic levels (from 3.9 
± 0.2 g before STZ to 4.0 ± 0.2 g 30 min after ivabradine injection, 3.8 ± 0.3 g 60 min after ivabradine 
injection, and 3.7 ± 0.3 g 120 min after ivabradine injection; P=0.789, P= 0.843, P=0.960, 
respectively) (Fig. 1E). Note that there is a small change in threshold following each saline injection, 
likely to be due to analgesia caused by the stress of handling and injection, but the analgesia caused 
by ivabradine injection is significantly greater, particularly after repeated injection.  
Finally, we examined whether this cumulative effect could also be seen with a more clinically 
relevant, spaced-out dosing regimen. We treated the animals with ivabradine twice a day, 3 hours 
before and 3 hours after pain threshold measurements over 4 consecutive days. Mechanical 
thresholds on days 2-4 in mice treated with ivabradine were not different from those recorded 
before STZ injection, and progressively increased compared to saline-treated animals (day 2, 
P=0.012; day 3, P=0.002; day 4, P=0.014). The analgesia was fully reversible, and cessation of 
treatment for 4 days resulted in a drop of mechanical thresholds back to diabetic levels. 
Because ivabradine inhibits all HCN isoforms, including HCN4 which is important for cardiac 
pacemaking, we investigated the effect of the drug on cardiac function using pulse oximetry. As 
expected, 5 mg/kg ivabradine caused a reduction in basal heart rate in control mice (29.2% at 30 min 
vs baseline, P<0.001) and a smaller reduction in diabetic mice (15.8% at 30 min, P=0.009 vs baseline, 
P=0.001 vs CTRL+IVA at 30 min; fig. S2). This lesser effect of ivabradine on diabetic cardiac function 
has also been documented in STZ rats (23). Ivabradine reduced respiratory rate (fig. S2B) in both 
control and diabetic mice, but no change was detected in oxygen saturation (fig. S2C) or pulse 
distention at 30 min post-injection (fig. S2D). There was no obvious effect on alertness or 
exploratory behavior as detected by visual observation. Put together, the pulse oximetry data 
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suggest that an analgesic dose of ivabradine is well tolerated in both control and diabetic mice, 
causing bradycardia but no other adverse effects on cardiac function. 
 
Peripheral HCN block is analgesic in Type 2 diabetes  
Type 2 diabetes is the most common form of diabetes in humans; therefore, we tested the effect of 
HCN block in the db/db mouse model of Type 2 diabetes, in which mice homozygous for a leptin 
receptor mutation (db/db) become obese in adulthood and show hyperglycemia together with an 
array of diabetic symptoms (24). At 18 weeks of age, all db/db mice were obese and hyperglycemic 
compared to heterozygous age-matched controls (db/+) (body weight db/db: 48 ± 0.6 g; db/+: 29.3 ± 
0.4 g; P<0.001; blood glucose db/db: 27 ± 1.3 mmol/L; db/+: 9.4 ± 0.4 mmol/L; P<0.001) (Fig. 2A). 
The db/db mice exhibited significantly lower mechanical pain thresholds (3.6 ± 0.2 g vs 4.5 ± 0.2 g, 
P<0.001) (Fig. 2B, C). Note that both the elevation in blood glucose and the mechanical hyperalgesia 
were less than those of Type 1 diabetic (STZ-injected) mice (compare Fig. 2 with Fig. 1A, B). A single 
ivabradine administration (5 mg/kg, i.p.) restored normal pain thresholds in db/db mice (from 3.6 ± 
0.2 g to 4.6 ± 0.2 g, P<0.001 vs saline at 60 min), whereas saline injection had no significant effect on 
pain threshold (P=0.47 at 60 min) compared to baseline (Fig. 2C).  
 
Induction of spinal c-Fos in diabetic mice is reversed by HCN inhibition 
We next sought a more direct way of demonstrating that enhanced excitability of peripheral 
nociceptive neurons is involved in diabetes-induced hyperalgesia. Activation of second-order 
neurons in the spinal cord by primary afferent input induces c-Fos, an immediate-early gene rapidly 
upregulated by neuronal activity (25). Therefore, C-FOS protein expression in neurons of the outer 
layers of the dorsal horn, where nociceptive fibers terminate, may be indicative of sustained 
peripheral nociceptive input and ongoing pain in diabetes. Quantification of C-FOS immunoreactivity 
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in lumbar spinal cord sections (laminae I-II) revealed an increased number of C-FOS positive neurons 
in the dorsal horn at 8 weeks after STZ administration, compared to controls (26.0 ± 2.6 vs 1.2 ± 0.2 
neurons/section, P<0.001) (Fig. 3). Although C-FOS activation was notably less compared to that 
induced by a strong noxious stimulus (fig. S3 and (26)), it is in agreement with previous studies in 
diabetes (27). Ivabradine treatment (three i.p. injections of 5 mg/kg every 2 hours, as in Fig. 1E) 
reduced diabetes-induced C-FOS activation 6 hours after the first injection (6.2 ± 0.4 
neurons/section, P<0.001 vs STZ). These data indicate that painful diabetic neuropathy increases 
activation of dorsal horn neurons, likely due to enhanced nociceptive input to the spinal cord, and 
that this activation can be reversed by pharmacological block of HCN in the periphery. 
 
Genetic deletion of HCN2 in nociceptive neurons prevents development of diabetic pain 
Ivabradine blocks all four HCN isoforms equally (22), so in order to decipher which HCN isoform 
causes hyperalgesia in diabetes we used a conditional knock-out mouse line in which HCN2  had 
been selectively deleted in nociceptive (Nav1.8-expressing) DRG neurons (HCN2 cKO) (10). STZ 
treatment of HCN2 cKO mice or their littermate controls (fHCN2) caused a similar hyperglycemia 
within one week (HCN2 cKO pre-STZ vs post-STZ, 7.8 ± 0.5 mmol/L vs 21.5 ± 1.4 mmol/l, P<0.001; 
fHCN2 pre-STZ vs post-STZ, 8.1 ± 0.3 mmol/L vs 25.2 ± 3.4, P<0.001) (Fig. 4A). High blood glucose 
concentrations were also present at 8 weeks (HCN2 cKO, 40.4 ± 0.6 mmol/l; fHCN2, 34.2 ± 6.3 
mmol/l, P<0.001 vs pre-STZ) (Fig. 4A). There was no significant difference between genotypes at any 
time point (1 week, P=0.07; 8 weeks, P=0.291), indicating that both genotypes become diabetic to an 
equal extent.  
We next studied the development of PDN in these transgenic mice. Diabetic fHCN2 mice, which are 
effectively wild-type, developed a progressive mechanical hypersensitivity, evident as a significant 
drop in mechanical thresholds compared to pre-diabetic baseline (2w, 3.7 ± 0.2 g; 4w, 3.4 ± 0.2 g; 
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6w, 3.1 ± 0.2 g; 8w, 3.2 ± 0.3 g), P<0.001 vs BL (4.2 ± 0.1 g) (Fig. 4B). When we assessed the HCN2 
cKO mice, however, we found no signs of mechanical hypersensitivity, despite the ongoing diabetes. 
Mechanical thresholds at 2, 4, 6, and 8 weeks post-STZ (4.2 ± 0.1 g, 4.2 ± 0.2 g, 4.3 ± 0.1 g and 4.4 ± 
0.1 g, respectively) were not significantly different to pre-diabetic values (4.2 ± 0.1 g; P=0.987, 
P=0.964, P=0.623, P=0.737, respectively) (Fig. 4B) and remained significantly higher than the 
corresponding values in the fHCN2 group (2w, P=0.037; 4-8w, P<0.001). 
Using C-FOS immunoreactivity in the dorsal horn as a measure of nociceptive activity impinging on 
second-order neurons of the spinal cord, we observed an increase in the numbers of C-FOS positive 
neurons in diabetic fHCN2 mice, whereas C-FOS expression was greatly reduced in diabetic HCN2 
cKO mice (15.6 ± 0.8 vs 1.4 ± 0.2 neurons/section, P<0.001) (Fig. 4C). Put together, these data 
suggest that genetic deletion of HCN2 in NaV1.8-positive nociceptors recapitulates the analgesia and 
suppression of peripheral nociceptive drive caused by pharmacological block of HCN channels, and 
therefore that HCN2 expressed in nociceptive neurons is necessary for diabetes-induced pain in the 
mouse STZ model. 
 
Diabetes reduces plantar skin innervation 
Intra-epidermal nerve fiber density is often used as a diagnostic criterion for peripheral neuropathy 
in human diabetic patients. We calculated intraepidermal nerve fiber density in plantar skin of the 
hindpaw by staining for PGP9.5, a pan-neuronal marker present in nerve terminals, and for collagen 
IV, which stains the basement membrane at the dermis-epidermis boundary. We also used DAPI 
stain to highlight the nuclei of basal layer cells of the basement membrane. With this combination of 
stains, nerve fibers crossing into the epidermis were clearly visualized (Fig. 5A). Quantification of 
intraepidermal nerve fiber density revealed a significant reduction in WT diabetic mice at 8 weeks 
post-STZ, compared to non-diabetic WT controls (26.8 ± 2.0 vs 44.2 ± 3.5 fibers/mm, respectively, 
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P=0.016) and this reduction was also present 8 weeks post-STZ in both fHCN2 mice (effectively WT) 
and in HCN2 cKO mice (fHCN2, 25.0 ± 2.6, P=0.023 vs control; HCN2 cKO, 28.1 ± 6.7 fibers/mm, 
P=0.014 vs control) (Fig. 5B).  These results confirm the peripheral neuropathy in the STZ mouse 
model and demonstrate that the lack of a pain phenotype in the HCN2 cKO mice is not due to a 
change in the denervation pattern. To further characterize the identity of affected intraepidermal 
fibers, we stained for calcitonin gene-related peptide (CGRP), which identifies peptidergic fibers, 
including transient receptor potential cation channel subfamily V member 1 (TRPV1) positive fibers 
that sense noxious heat. Diabetes reduced intraepidermal CGRP+ fibers from 17.4 ± 0.8 to 12.5 ± 0.6 
fibers/mm (Fig. 5C, P=0.006; bottom left graph). Because most TRPV1+ fibers in mouse co-express 
CGRP (28), this reduction is in agreement with the observed thermal hyposensitivity in STZ mice (Fig. 
1C). Indeed, there was a significant inverse correlation between intraepidermal CGRP+ fiber density 
and heat pain thresholds in diabetic mice (R2=0.88, P=0.006; bottom right graph). 
 
Diabetes does not affect HCN2 expression in sensory neurons 
The preceding experiments show that enhanced peripheral HCN2 function plays a critical role in    
pain and mechanical hypersensitivity in diabetes. To determine whether this is due to an 
upregulation of HCN2 expression in sensory neurons, we used immunohistochemistry to visualize 
HCN2 in lumbar DRG sections (Fig. 6A). In control animals, HCN2 immunoreactivity was detected in 
73.2  4.5% of all neurons, as revealed by co-localization with the pan-neuronal marker β3-tubulin 
(examples denoted by arrows). As previously reported, HCN2 was detected in a range of cell sizes, 
including most small diameter neurons, the majority of which are nociceptive, as well as in larger 
neurons with a characteristic membrane ring staining (29). In diabetic animals at 8 weeks post-STZ, 
the percentage of HCN2-positive neurons was 72.5  7.0%, not significantly different from control 
(P=0.934) (Fig. 6B, left). In addition, the distribution of HCN2+ neurons amongst sub-classes of DRG 
neurons (small, medium, and large diameter classes) was also not different between control and 
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diabetic (P=0.116; Fig. 6B, middle). When examining staining intensity in HCN2-positive neurons, we 
found no effect of diabetes amongst all neurons (control, 3.5  0.2 A.U. vs diabetic, 3.9  0.1 A.U., 
P=0.102) or amongst DRG sub-populations (P=0.802) (Fig. 6B, right). The specificity of the HCN2 
antibody was confirmed by detection of HCN2 in small NaV1.8+ nociceptive DRG neurons of WT mice 
but not of HCN2 cKO mice, as well as by the complete lack of HCN2 immunoreactivity in DRG from 
global HCN2 knockout mice (Fig. 6C). 
We investigated whether enhanced HCN2 function could be due to changes not reflected in the cell 
soma (such as axonal trafficking), by examining HCN2 expression in the sciatic nerve. The intensity of 
axonal HCN2 staining was similar between control and STZ mice at 8 weeks (2.6  0.1 A.U. vs 2.6  
0.6 A.U., P=0.871), suggesting that there is no change in axonal HCN2 expression in diabetes (fig. 
S4A). We did not detect any HCN2 in epidermal nerve fibers of control mice, probably because the 
channel is present in low quantities in the very fine peripheral nerve endings (fig. S4B). 
We also examined expression and regulation by diabetes of the other HCN isoforms in DRG neurons. 
HCN1 was predominantly localized in medium-large neurons (fig. S5), with no difference between 
control and diabetic conditions in overall proportion of HCN1+ neurons, distribution of HCN1+ 
neurons amongst size classes, or intensity of stain as a function of cell size. The HCN3 isoform was 
detected in a mixture of neurons of all sizes (fig. S6) and there was no effect of diabetes on either 
proportion of HCN3+ neurons or stain intensity as a function of size.  HCN4 was found mainly in 
medium-large neurons (fig. S7), and again there was no effect of diabetes on any parameter. Overall, 
the immunohistological data show that diabetes does not induce upregulation of any HCN isoform at 
the protein level. Note that a previous study reported that diabetes increases HCN expression and 
currents in parasympathetic neurons of the nodose ganglion, suggesting that HCN channels may be 
differentially regulated in autonomic neuropathy (19). 
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Diabetes does not change electrophysiological properties of isolated nociceptive neurons  
We next examined the in vitro electrophysiological properties of small DRG neurons (<20 μm 
diameter, predominantly nociceptive in nature (30)) from control and STZ mice, to determine 
whether diabetes alters HCN ion channel properties. In response to steady current injection, 
neurons from STZ and non-diabetic mice showed a similar increase in firing frequency with 
increasing injected current, reaching a similar plateau level (14.58  1.87 spikes/sec vs 16.45  2.99 
spikes/sec, Fig. 7A&B). Exposure to 50 μM forskolin, which increases intracellular cyclic adenosine 
mono phosphate (cAMP) and shifts the activation curve of HCN2 to a more positive membrane 
voltage, increased firing frequency after current injection, from 13.51  2.26 spikes/sec to 21.68  
2.72 spikes/sec (40 pA, P<0.001) and from 14.58  1.87 spikes/sec to 24.0  2.94 spikes/sec (50 pA, 
P=0.009). The cAMP-dependent sensitization of neuronal firing was also reflected in a change in the 
pattern of firing, from phasic (steady current elicits one or a few spikes) to tonic (firing continues 
throughout current injection; see Fig. 7C and (31)). The proportion of phasic/tonic firing neurons was 
similar between STZ and non-diabetic mice at baseline (Fig. 7D, P>0.05) and cAMP augmented tonic 
firing (P=0.043 and P=0.081, respectively) with no significant difference between groups (Fig. 7D, 
P=0.652).   
We used voltage clamp to compare maximum current densities in nociceptive neurons by fully 
activating HCN channels with a hyperpolarizing voltage step from -60 mV to -140 mV. Similar 
maximal current amplitudes were observed in STZ and control mice and in the presence or absence 
of forskolin, showing that maximum current density is not affected by diabetes nor by cAMP 
increase (Fig. 7E) (P=0.545). This result supports the immunohistological data that showed no 
upregulation of HCN2 expression in diabetic neuropathy.  
We examined the effect of cAMP on the voltage dependence of HCN channel activation in small DRG 
neurons from STZ and non-diabetic mice. Forskolin caused a depolarizing shift in HCN half-activation 
voltage (V½) in both STZ (+10.83 mV, P<0.001 vs pre-forskolin, -97.1  1.6 mV) and control neurons 
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(+12.36 mV, P<0.001 vs pre-forskolin, -99.0  1.1 mV) (Fig. 7F). However, the magnitude of the shift 
was not significantly different between diabetic and control neurons (P=0.779). Finally, to investigate 
the possibility that the altered concentration of glucose in diabetes might affect the function of HCN 
channels, we compared Ih currents in neurons in extracellular solutions containing either low (5 mM) 
or high (25 mM) glucose. Glucose concentration had no effect on activation curves or current 
densities in either control or STZ neurons (fig. S8). 
 
PDN is associated with increased cAMP in sensory neurons 
The immunohistochemical and electrophysiological experiments above show that diabetes does not 
cause any change in expression of HCN2 nor in the electrophysiological properties of isolated 
nociceptive neurons. The marked effect of diabetic neuropathy on HCN2 function in vivo could 
instead be due to factors which are present in diabetes and potentiate HCN2 function, but are 
rapidly lost after neuronal isolation. The most likely way in which these unidentified factors might 
act is by causing an increase of intracellular cAMP concentration in nociceptive neurons, resulting in 
a potentiation of HCN2 activation through a positive shift in its activation curve on the voltage axis. 
We therefore examined the effect of diabetes on the cAMP content in whole DRG from control and 
diabetic mice.   Analysis of DRG tissue from STZ-treated mice in which prominent mechanical 
hypersensitivity had been verified through behavioral tests showed that the cAMP content was 
increased more than 8-fold (non-diabetic, 3.1  1.6 pmol/mg; STZ pain, 26.6  10.3 pmol/mg of total 
protein; P=0.014). When samples from fully diabetic mice which did not exhibit substantial 
mechanical hypersensitivity were assessed (STZ no pain), cAMP concentrations were not significantly 
different from non-diabetic controls (P=0.811 vs non-diabetic) (Fig. 8A).  
Apart from binding directly to HCN ion channels, cAMP can also activate the cAMP-dependent 
protein kinase A (PKA), potentially causing phosphorylation of other targets involved in pain 
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transduction, such as NaV1.8 and TRPV1. We therefore investigated the effect of the PKA inhibitor H-
89 on diabetes-induced hyperalgesia, at doses found to be effective in reducing prostaglandin E2 
(PGE2)-induced inflammatory pain (fig. S9) (32), Systemic treatment with 5 mg/kg H-89 had some 
effect in increasing mechanical pain thresholds 8 weeks after STZ (P<0.05 vs post-STZ), but the 
magnitude of this effect was smaller compared to the effect of ivabradine (P<0.05 ivabradine vs H-89 
at any dose) (Fig. 8B).
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Discussion 
PDN is a typical ‘die-back’ neuropathy, in which unmyelinated C-fibers and thinly myelinated A 
nociceptive fibers retreat first (33, 34), and in which spontaneous firing develops in small fibers (5, 6, 
35). The work reported here provides further support for the idea of spontaneous firing in small 
nociceptive nerve fibers, because in diabetic mice C-FOS, which is an index of nociceptive afferent 
activity (25), is induced in outer layers of the dorsal horn, where nociceptive afferents terminate. A 
critical role for the HCN2 ion channel in maintaining the firing in small-diameter afferent nerve 
fibers, and thus in promoting the pain of diabetes, is supported by: (1) the complete suppression of 
pain in mouse models of Type 1 and Type 2 diabetes by the HCN channel blocker ivabradine, which 
does not distinguish between HCN isoforms but is peripherally restricted (18), therefore localizing 
the site of HCN block to the peripheral nervous system; (2) the similar suppression of the pain 
associated with diabetes caused by deletion of HCN2 in the NaV1.8-expressing population of nerve 
fibers, which are predominantly small unmyelinated C-fibers (36, 37); and (3) the reduction in C-FOS 
expression in the dorsal horn achieved both by blocking HCN channels with ivabradine and by 
genetically deleting HCN2 in NaV1.8-expressing nerve fibers.  
As many as 80% of diabetic patients with reduced small-fiber skin innervation, caused by nerve 
degeneration, also exhibit hyposensitivity to heat (3, 38, 39), which is consistent with the 
preferential expression of the heat-sensitive ion channel TRPV1 in small unmyelinated nerve fibers 
(40). Indeed, an inverse correlation between TRPV1+ fiber skin innervation and heat detection has 
been directly demonstrated in diabetic patients (41), and we also found an association between 
degeneration of peptidergic intraepidermal nerve fibers (which include TRPV1+ fibers) and increased 
heat thresholds in STZ-treated mice.  
The painful sensation caused by light touch, known as mechanical allodynia, which is one of the 
most unpleasant features of PDN, is likely  to be conveyed by large myelinated fibers (42). In 
agreement with this, preventing conduction in large myelinated fibers alleviates mechanical 
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allodynia in PDN (43). How can spontaneous activity in small HCN2-expressing unmyelinated fibers 
enhance the sensation of mechanical allodynia, which is conveyed via large myelinated fibers? A 
probable explanation lies in the phenomenon of central sensitization, in which activation of small 
nociceptive nerve fibers causes a sensation of mechanical allodynia, conveyed via large fibers. 
Central sensitization is thought to be a result of neural plasticity in the dorsal horn, in which afferent 
mechanoreceptor input is switched from second-order neurons signaling innocuous light touch, to 
second-order neurons signaling a sensation of pain (44). 
One possible explanation for increased firing in nociceptive fibers in the mouse model of diabetes 
could be an upregulation of HCN2 expression in sensory neurons, but both immunohistochemical 
and electrophysiological approaches indicate that HCN2 protein expression and maximal current 
density were not different in neurons isolated from diabetic and non-diabetic mice. In sensory 
neurons, however, HCN2 function can be potentiated by an increased intracellular cAMP, which we 
found to be elevated in DRG from the mouse model of diabetes. Interaction of cAMP with the cyclic 
nucleotide binding domain in the C-terminal region of HCN2 results in a depolarizing shift in the 
voltage dependence of activation, leading to an enhanced inward current carried by HCN2 and thus 
to augmented spontaneous and evoked firing (10). In agreement, raising cAMP concentrations with 
forskolin in vitro shifted the voltage dependence of Ih towards more positive membrane voltages 
and increased firing rates in small neurons both in the animal model of type 1 diabetes and in 
control animals, and previous work has shown that both the shift in Ih and the increased firing rate 
depend on HCN2 (10).  
The mechanisms by which cAMP is elevated in diabetes have not been determined in the present 
study, but are unlikely to involve only inflammatory mediators released at a peripheral location 
where neurodegeneration takes place, because we found an increase in cAMP in DRG cell bodies, 
some distance from the site of neurodegeneration. In other pain states, cAMP can be increased by 
binding of PGE2 or other inflammatory mediators to GPCRs, such as the prostaglandin E2 receptor 4 
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(EP4), resulting in activation of adenylate cyclase and increased cAMP production (10). Several lines 
of evidence support the idea that diabetes is also associated with a similar pro-inflammatory 
phenotype. Diabetic neuropathy increases the amounts of inflammatory mediators in the DRG and 
sciatic nerve of rodents as well as in human blood (45-48). Administration of inhibitors of adenylate 
cyclase restores mechanical thresholds in diabetic rats, whereas cAMP analogs have the opposite 
effect (49). The expression of cyclooxygenase-2 (COX-2), which is upstream of PGE2, is increased in 
diabetic DRG (50) and in sciatic nerve (51), and bradykinin-induced PGE2 secretion is also 
potentiated by diabetes (52). In support of a sensitizing role of cAMP in sensory neurons, COX-2 
inhibitors are analgesic in diabetic mouse models when applied peripherally but not intrathecally 
(53, 54) and COX-2 knock-out mice have attenuated signs of peripheral neuropathy after induction 
of diabetes (55). Other pro-inflammatory pathways may also be involved in activating adenylate 
cyclase and so increasing levels of cAMP. 
Increased cAMP also activates PKA, which in turn phosphorylates other ion channels in the pain 
pathway, such as Nav1.8 (56) and TRPV1 (57). Although an involvement of PKA-dependent 
sensitization of these channels in PDN is possible (58), the complete abolition of hypersensitivity 
either by an HCN blocker with few off-target actions (18) or by genetic deletion of HCN2 strongly 
suggests that HCN2 has the major influence in diabetes-induced hyperalgesia. This point is further 
substantiated by the much larger effect of ivabradine on diabetic mechanical pain thresholds 
compared to that of the PKA inhibitor H-89. 
We propose that HCN2 sensitization, mediated by increased intracellular cAMP, mediates pain in 
diabetes both by causing spontaneous firing in nociceptive nerve fibers, due to HCN2 activation at 
the resting membrane potential, and by promoting higher spiking frequencies in response to a 
painful stimulus, due to a more rapid “pacemaker” depolarization rate between action potentials. 
Central sensitization is then activated by the enhanced firing in small nociceptive afferents and 
causes mechanical allodynia, a painful sensation initiated by activation of large fibers by tactile 
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stimuli. The occurrence of spontaneous firing in C-fibers in STZ-treated rodents has been directly 
demonstrated using microneurography (6). We found evidence supporting the idea of increased 
peripheral nociceptive drive in diabetic mice by using C-FOS staining. In addition, diabetes-induced 
enhancement of firing frequency in C polymodal nociceptors has been reported using a skin-nerve 
preparation (35).  
Diabetic rats treated with the potent TRPV1 agonist resiniferatoxin, which is neurotoxic to the 
TRPV1-expressing subpopulation of C-fibers, maintain mechanical allodynia (59), an observation 
which is often cited as indicating that C-fibers are not involved in PDN. However, two major classes 
of C-fibers are unaffected by resiniferatoxin, namely nociceptive non-peptidergic C-fibers expressing 
the receptor MAS Related GPR Family Member D (MRGPRD), and low-threshold mechanoreceptors 
(60). Activity in these C-fibers may be able to drive central sensitization and so cause mechanical 
allodynia.  
Patients with neuropathic pain exhibit a variety of positive symptoms, for example hyperalgesia and 
spontaneous pain, together with negative symptoms such as sensory loss, and different treatments 
may be appropriate depending on the symptoms displayed (61). In that context, our results may be 
particularly relevant for diabetic patients in which ongoing pain, likely to be driven by spontaneous 
activity in peripheral nerves, is a prominent feature. Microneurography studies in humans have 
shown that peripheral nerve activity is routinely present in neuropathic pain syndromes involving 
peripheral neuropathy (62-64), including diabetic neuropathy (65), and that the incidence of 
spontaneous activity is higher when accompanied by reports of ongoing pain (7). We note, however, 
that there may not be an invariant link between spontaneous activity in peripheral nerves and 
ongoing pain, as a number of studies have proposed that changes in CNS processing can also 
influence the pain of diabetic neuropathy. Potential CNS events affecting neuropathic pain include 
microglial activation in the spinal cord (66), reduced thalamic activity and communication with 
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cortex (67), loss of gray matter in the thalamus and somatosensory cortex (68), and impaired 
descending modulation (69).  
Intriguingly, we found that repeated treatment with ivabradine provided superior analgesia 
compared to single administration. Although the mechanism underlying this cumulative effect is not 
clear, it has been documented before (70) and may indicate the existence of a long-lived ivabradine 
metabolite, similar to the morphine metabolite morphine-6-glucuronide (M6G), which is 10-fold 
more potent that morphine itself (71). Ivabradine is already used clinically to treat angina pectoris 
via inhibition of HCN-dependent firing in cardiac pacemaker cells, which slows heart rate and 
reduces the oxygen demand of cardiac muscle. The established clinical experience and available 
pharmacological profiling means that ivabradine could be swiftly assessed in PDN trials.  One 
consideration will be the bradycardic effect due to HCN4 inhibition in the sinoatrial node; 
nevertheless, a previous study of ivabradine for diabetes-associated coronary artery disease showed 
a good safety profile with no notable bradycardia, visual disturbances, or adverse effects on glucose 
metabolism (72). In addition, we demonstrate here that targeted genetic deletion of HCN2 in the 
periphery gives effective pain relief without detectable side effects. Therefore, the discovery of CNS-
excluded and HCN2-selective inhibitors is likely to provide marked analgesia in PDN, together with a 
safe pharmacological profile.  
HCN2 channels are closed and generate no inward current over the normal range of the action 
potential, because their voltage range of activation is negative under non-pathological conditions 
(9). An important consequence of that is that blockade of HCN2 channels has no effect on baseline 
neuronal excitability, nor does it modulate pain thresholds under normal conditions. This is in 
contrast to the effects of blocking Nav channels with local anesthetic, which produces total 
insensibility to pain, or of human genetic deletion of Nav1.7, which causes complete analgesia even 
under normal conditions, with consequent self-injury (73). We propose here that in pathological pain 
states, including PDN, HCN2 channels are recruited as initiators of spontaneous activity only when 
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the voltage range of activation undergoes a positive shift after interaction of inflammatory 
mediators with Gs-coupled receptors and a consequent elevation of intracellular cAMP. Thus, HCN2 
channels are an ideal analgesic target, because their blockade has an analgesic effect only under 
pathological conditions and should have no effect on normal nociception. 
 
Materials and Methods 
 
Study design 
The main objective of this study was to test the effect of pharmacological or genetic inhibition of 
HCN2 on pain in diabetic mice. For behavioral assessment, animals were randomly chosen from 
multiple cages, provided they satisfied the inclusion criteria outlined in detail in the ‘diabetes 
models’ section below. Sample sizes for animal behavior, histology, biochemistry, and 
electrophysiology were chosen based on previous experience with these assays as the minimum 
number of independent observations expected to achieve statistical significance. All behavioral 
testing was conducted during the day in a quiet temperature-controlled room by an experimenter 
blinded to the identity of drug treatment and/or mouse genotype.  
 
Statistical analysis  
All data are presented as mean ± standard error of the mean (SEM), and group sizes are noted in 
each figure legend. All replicates refer to biological replicates. Statistical significance was determined 
with Prism (GraphPad Software) or SigmaPlot (Systat Software Inc.) using unpaired, equal variance, 
two-tailed Student’s t-test, linear regression analysis, chi-square test, one-way analysis of variance 
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(ANOVA), two-way ANOVA, or two-way ANOVA with repeated measures (RM) and Student–
Newman–Keuls or Bonferroni tests (for post hoc analysis), as indicated in the corresponding figure 
legends. Significance is indicated by: *, P<0.05; **, P<0.01; ***, P<0.001. A p-value of P<0.05 was 
considered significant.  
 
Supplementary Materials 
Supplementary materials and methods 
Figure S1: No effect of ivabradine on heat thresholds in naïve or diabetic mice 
Figure S2: Effect of ivabradine on cardiac parameters in vivo 
Figure S3: C-FOS induction in the spinal cord 2 hours after Complete Freund's Adjuvant (CFA)   
Figure S4: No regulation of axonal HCN2 expression by diabetes 
Figure S5: HCN1 expression in control and diabetic DRG neurons 
Figure S6: HCN3 expression in control and diabetic DRG neurons 
Figure S7: HCN4 expression in control and diabetic DRG neurons 
Figure S8: No effect of high glucose on properties of Ih in nociceptive neurons 
Figure S9: Reduction of PGE2-induced inflammatory pain by systemic H-89 treatment in naïve mice 
 
 
23 
 
References and Notes 
1. A. K. Schreiber, C. F. Nones, R. C. Reis, J. G. Chichorro, J. M. Cunha, Diabetic neuropathic 
pain: Physiopathology and treatment. World journal of diabetes 6, 432-444 (2015). 
2. M. Polydefkis, P. Hauer, S. Sheth, M. Sirdofsky, J. W. Griffin, J. C. McArthur, The time course 
of epidermal nerve fibre regeneration: studies in normal controls and in people with 
diabetes, with and without neuropathy. Brain : a journal of neurology 127, 1606-1615 
(2004). 
3. C. T. Shun, Y. C. Chang, H. P. Wu, S. C. Hsieh, W. M. Lin, Y. H. Lin, T. Y. Tai, S. T. Hsieh, Skin 
denervation in type 2 diabetes: correlations with diabetic duration and functional 
impairments. Brain : a journal of neurology 127, 1593-1605 (2004). 
4. J. Zenker, D. Ziegler, R. Chrast, Novel pathogenic pathways in diabetic neuropathy. Trends 
Neurosci 36, 439-449 (2013). 
5. K. J. Burchiel, L. C. Russell, R. P. Lee, A. A. Sima, Spontaneous activity of primary afferent 
neurons in diabetic BB/Wistar rats. A possible mechanism of chronic diabetic neuropathic 
pain. Diabetes 34, 1210-1213 (1985). 
6. J. Serra, H. Bostock, R. Sola, J. Aleu, E. Garcia, B. Cokic, X. Navarro, C. Quiles, 
Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic 
pain states in humans and rats. Pain 153, 42-55 (2012). 
7. K. Orstavik, B. Namer, R. Schmidt, M. Schmelz, M. Hilliges, C. Weidner, R. W. Carr, H. 
Handwerker, E. Jorum, H. E. Torebjork, Abnormal function of C-fibers in patients with 
diabetic neuropathy. J Neurosci 26, 11287-11294 (2006). 
8. E. C. Emery, G. T. Young, P. A. McNaughton, HCN2 ion channels: an emerging role as the 
pacemakers of pain. Trends Pharmacol Sci 33, 456-463 (2012). 
9. C. Tsantoulas, E. R. Mooney, P. A. McNaughton, HCN2 ion channels: basic science opens up 
possibilities for therapeutic intervention in neuropathic pain. Biochem J 473, 2717-2736 
(2016). 
10. E. C. Emery, G. T. Young, E. M. Berrocoso, L. Chen, P. A. McNaughton, HCN2 ion channels 
play a central role in inflammatory and neuropathic pain. Science 333, 1462-1466 (2011). 
11. S. R. Chaplan, H. Q. Guo, D. H. Lee, L. Luo, C. Liu, C. Kuei, A. A. Velumian, M. P. Butler, S. M. 
Brown, A. E. Dubin, Neuronal hyperpolarization-activated pacemaker channels drive 
neuropathic pain. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 23, 1169-1178 (2003). 
12. A. Momin, H. Cadiou, A. Mason, P. A. McNaughton, Role of the hyperpolarization-activated 
current Ih in somatosensory neurons. The Journal of physiology 586, 5911-5929 (2008). 
13. J. Stieber, S. Herrmann, S. Feil, J. Loster, R. Feil, M. Biel, F. Hofmann, A. Ludwig, The 
hyperpolarization-activated channel HCN4 is required for the generation of pacemaker 
action potentials in the embryonic heart. Proceedings of the National Academy of Sciences of 
the United States of America 100, 15235-15240 (2003). 
14. M. Baruscotti, A. Bucchi, C. Viscomi, G. Mandelli, G. Consalez, T. Gnecchi-Rusconi, N. 
Montano, K. R. Casali, S. Micheloni, A. Barbuti, D. DiFrancesco, Deep bradycardia and heart 
block caused by inducible cardiac-specific knockout of the pacemaker channel gene Hcn4. 
Proceedings of the National Academy of Sciences of the United States of America 108, 1705-
1710 (2011). 
15. H. J. Cho, V. Staikopoulos, J. J. Ivanusic, E. A. Jennings, Hyperpolarization-activated cyclic-
nucleotide gated 4 (HCN4) protein is expressed in a subset of rat dorsal root and trigeminal 
ganglion neurons. Cell Tissue Res 338, 171-177 (2009). 
16. E. V. Kouranova, B. W. Strassle, R. H. Ring, M. R. Bowlby, D. V. Vasilyev, Hyperpolarization-
activated cyclic nucleotide-gated channel mRNA and protein expression in large versus small 
24 
 
diameter dorsal root ganglion neurons: correlation with hyperpolarization-activated current 
gating. Neuroscience 153, 1008-1019 (2008). 
17. O. Postea, M. Biel, Exploring HCN channels as novel drug targets. Nature reviews. Drug 
discovery 10, 903-914 (2011). 
18. G. T. Young, E. C. Emery, E. R. Mooney, C. Tsantoulas, P. A. McNaughton, Inflammatory and 
neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated 
cyclic nucleotide-gated ion channels. Pain 155, 1708-1719 (2014). 
19. H. Tu, L. Zhang, T. P. Tran, R. L. Muelleman, Y. L. Li, Diabetes alters protein expression of 
hyperpolarization-activated cyclic nucleotide-gated channel subunits in rat nodose ganglion 
cells. Neuroscience 165, 39-52 (2010). 
20. Y. L. Li, T. P. Tran, R. Muelleman, H. D. Schultz, Blunted excitability of aortic baroreceptor 
neurons in diabetic rats: involvement of hyperpolarization-activated channel. Cardiovasc Res 
79, 715-721 (2008). 
21. D. A. Andersson, M. R. Filipovic, C. Gentry, M. Eberhardt, N. Vastani, A. Leffler, P. Reeh, S. 
Bevan, Streptozotocin Stimulates the Ion Channel TRPA1 Directly: INVOLVEMENT OF 
PEROXYNITRITE. J Biol Chem 290, 15185-15196 (2015). 
22. J. Stieber, K. Wieland, G. Stockl, A. Ludwig, F. Hofmann, Bradycardic and proarrhythmic 
properties of sinus node inhibitors. Mol Pharmacol 69, 1328-1337 (2006). 
23. X. Huang, N. Zhong, H. Zhang, A. Ma, Z. Yuan, N. Guo, Reduced expression of HCN channels 
in the sinoatrial node of streptozotocin-induced diabetic rats. Can J Physiol Pharmacol 95, 
586-594 (2017). 
24. A. A. Sima, D. M. Robertson, Peripheral neuropathy in mutant diabetic mouse [C57BL/Ks 
(db/db)]. Acta Neuropathol 41, 85-89 (1978). 
25. S. P. Hunt, A. Pini, G. Evan, Induction of c-fos-like protein in spinal cord neurons following 
sensory stimulation. Nature 328, 632-634 (1987). 
26. M. J. Caterina, A. Leffler, A. B. Malmberg, W. J. Martin, J. Trafton, K. R. Petersen-Zeitz, M. 
Koltzenburg, A. I. Basbaum, D. Julius, Impaired nociception and pain sensation in mice 
lacking the capsaicin receptor. Science 288, 306-313 (2000). 
27. C. Morgado, I. Tavares, C-fos expression at the spinal dorsal horn of streptozotocin-induced 
diabetic rats. Diabetes/metabolism research and reviews 23, 644-652 (2007). 
28. D. J. Cavanaugh, A. T. Chesler, J. M. Braz, N. M. Shah, D. Julius, A. I. Basbaum, Restriction of 
transient receptor potential vanilloid-1 to the peptidergic subset of primary afferent neurons 
follows its developmental downregulation in nonpeptidergic neurons. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 31, 10119-10127 (2011). 
29. T. Smith, M. Al Otaibi, J. Sathish, L. Djouhri, Increased expression of HCN2 channel protein in 
L4 dorsal root ganglion neurons following axotomy of L5- and inflammation of L4-spinal 
nerves in rats. Neuroscience 295, 90-102 (2015). 
30. C. J. Woolf, Q. Ma, Nociceptors--noxious stimulus detectors. Neuron 55, 353-364 (2007). 
31. R. Yoshimoto, S. Iwasaki, H. Takago, T. Nakajima, Y. Sahara, K. Kitamura, Developmental 
increase in hyperpolarization-activated current regulates intrinsic firing properties in rat 
vestibular ganglion cells. Neuroscience 284, 632-642 (2015). 
32. K. O. Aley, J. D. Levine, Role of protein kinase A in the maintenance of inflammatory pain. J 
Neurosci 19, 2181-2186 (1999). 
33. M. J. Brown, J. R. Martin, A. K. Asbury, Painful diabetic neuropathy. A morphometric study. 
Arch Neurol 33, 164-171 (1976). 
34. R. J. Guy, C. A. Clark, P. N. Malcolm, P. J. Watkins, Evaluation of thermal and vibration 
sensation in diabetic neuropathy. Diabetologia 28, 131-137 (1985). 
35. Y. Suzuki, J. Sato, M. Kawanishi, K. Mizumura, Lowered response threshold and increased 
responsiveness to mechanical stimulation of cutaneous nociceptive fibers in streptozotocin-
diabetic rat skin in vitro--correlates of mechanical allodynia and hyperalgesia observed in the 
early stage of diabetes. Neuroscience research 43, 171-178 (2002). 
25 
 
36. L. C. Stirling, G. Forlani, M. D. Baker, J. N. Wood, E. A. Matthews, A. H. Dickenson, M. A. 
Nassar, Nociceptor-specific gene deletion using heterozygous NaV1.8-Cre recombinase mice. 
Pain 113, 27-36 (2005). 
37. S. D. Shields, H. S. Ahn, Y. Yang, C. Han, R. P. Seal, J. N. Wood, S. G. Waxman, S. D. Dib-Hajj, 
Nav1.8 expression is not restricted to nociceptors in mouse peripheral nervous system. Pain 
153, 2017-2030 (2012). 
38. G. L. Pittenger, M. Ray, N. I. Burcus, P. McNulty, B. Basta, A. I. Vinik, Intraepidermal nerve 
fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients. 
Diabetes Care 27, 1974-1979 (2004). 
39. S. Loseth, E. Stalberg, R. Jorde, S. I. Mellgren, Early diabetic neuropathy: thermal thresholds 
and intraepidermal nerve fibre density in patients with normal nerve conduction studies. J 
Neurol 255, 1197-1202 (2008). 
40. M. J. Caterina, D. Julius, The vanilloid receptor: a molecular gateway to the pain pathway. 
Annu Rev Neurosci 24, 487-517 (2001). 
41. P. Facer, M. A. Casula, G. D. Smith, C. D. Benham, I. P. Chessell, C. Bountra, M. Sinisi, R. Birch, 
P. Anand, Differential expression of the capsaicin receptor TRPV1 and related novel 
receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and 
diabetic neuropathy. BMC Neurol 7, 11 (2007). 
42. L. Li, M. Rutlin, V. E. Abraira, C. Cassidy, L. Kus, S. Gong, M. P. Jankowski, W. Luo, N. Heintz, 
H. R. Koerber, C. J. Woodbury, D. D. Ginty, The functional organization of cutaneous low-
threshold mechanosensory neurons. Cell 147, 1615-1627 (2011). 
43. Z. Z. Xu, Y. H. Kim, S. Bang, Y. Zhang, T. Berta, F. Wang, S. B. Oh, R. R. Ji, Inhibition of 
mechanical allodynia in neuropathic pain by TLR5-mediated A-fiber blockade. Nat Med 21, 
1326-1331 (2015). 
44. A. Latremoliere, C. J. Woolf, Central sensitization: a generator of pain hypersensitivity by 
central neural plasticity. J Pain 10, 895-926 (2009). 
45. C. Herder, J. Baumert, A. Zierer, M. Roden, C. Meisinger, M. Karakas, L. Chambless, W. 
Rathmann, A. Peters, W. Koenig, B. Thorand, Immunological and cardiometabolic risk factors 
in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-
cohort study. PLoS One 6, e19852 (2011). 
46. N. M. Wilson, D. E. Wright, Inflammatory Mediators in Diabetic Neuropathy. Journal of 
diabetes & metabolism 01,  (2012). 
47. C. Herder, M. Lankisch, D. Ziegler, W. Rathmann, W. Koenig, T. Illig, A. Doring, B. Thorand, R. 
Holle, G. Giani, S. Martin, C. Meisinger, Subclinical inflammation and diabetic 
polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes care 32, 680-682 
(2009). 
48. J. Ma, P. Pan, M. Anyika, B. S. Blagg, R. T. Dobrowsky, Modulating Molecular Chaperones 
Improves Mitochondrial Bioenergetics and Decreases the Inflammatory Transcriptome in 
Diabetic Sensory Neurons. ACS Chem Neurosci 6, 1637-1648 (2015). 
49. S. C. Ahlgren, J. D. Levine, Mechanical hyperalgesia in streptozotocin-diabetic rats. 
Neuroscience 52, 1049-1055 (1993). 
50. H. T. Cheng, J. R. Dauch, S. S. Oh, J. M. Hayes, Y. Hong, E. L. Feldman, p38 mediates 
mechanical allodynia in a mouse model of type 2 diabetes. Molecular pain 6, 28 (2010). 
51. R. Pop-Busui, V. Marinescu, C. Van Huysen, F. Li, K. Sullivan, D. A. Greene, D. Larkin, M. J. 
Stevens, Dissection of metabolic, vascular, and nerve conduction interrelationships in 
experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine 
administration. Diabetes 51, 2619-2628 (2002). 
52. D. Fuchs, F. Birklein, P. W. Reeh, S. K. Sauer, Sensitized peripheral nociception in 
experimental diabetes of the rat. Pain 151, 496-505 (2010). 
26 
 
53. S. Kimura, H. Kontani, Demonstration of antiallodynic effects of the cyclooxygenase-2 
inhibitor meloxicam on established diabetic neuropathic pain in mice. Journal of 
pharmacological sciences 110, 213-217 (2009). 
54. I. E. Juarez-Rojop, P. E. Morales-Hernandez, C. A. Tovilla-Zarate, D. Y. Bermudez-Ocana, J. E. 
Torres-Lopez, J. L. Ble-Castillo, J. C. Diaz-Zagoya, V. Granados-Soto, Celecoxib reduces 
hyperalgesia and tactile allodynia in diabetic rats. Pharmacological reports : PR 67, 545-552 
(2015). 
55. A. P. Kellogg, T. D. Wiggin, D. D. Larkin, J. M. Hayes, M. J. Stevens, R. Pop-Busui, Protective 
effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and 
intraepidermal nerve fiber loss in experimental diabetes. Diabetes 56, 2997-3005 (2007). 
56. E. M. Fitzgerald, K. Okuse, J. N. Wood, A. C. Dolphin, S. J. Moss, cAMP-dependent 
phosphorylation of the tetrodotoxin-resistant voltage-dependent sodium channel SNS. J 
Physiol 516 ( Pt 2), 433-446 (1999). 
57. G. Bhave, W. Zhu, H. Wang, D. J. Brasier, G. S. Oxford, R. W. t. Gereau, cAMP-dependent 
protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct 
phosphorylation. Neuron 35, 721-731 (2002). 
58. K. O. Aley, J. D. Levine, Different peripheral mechanisms mediate enhanced nociception in 
metabolic/toxic and traumatic painful peripheral neuropathies in the rat. Neuroscience 111, 
389-397 (2002). 
59. G. M. Khan, S. R. Chen, H. L. Pan, Role of primary afferent nerves in allodynia caused by 
diabetic neuropathy in rats. Neuroscience 114, 291-299 (2002). 
60. D. J. Cavanaugh, H. Lee, L. Lo, S. D. Shields, M. J. Zylka, A. I. Basbaum, D. J. Anderson, Distinct 
subsets of unmyelinated primary sensory fibers mediate behavioral responses to noxious 
thermal and mechanical stimuli. Proc Natl Acad Sci U S A 106, 9075-9080 (2009). 
61. R. Baron, C. Maier, N. Attal, A. Binder, D. Bouhassira, G. Cruccu, N. B. Finnerup, M. Haanpaa, 
P. Hansson, P. Hullemann, T. S. Jensen, R. Freynhagen, J. D. Kennedy, W. Magerl, T. Mainka, 
M. Reimer, A. S. Rice, M. Segerdahl, J. Serra, S. Sindrup, C. Sommer, T. Tolle, J. Vollert, R. D. 
Treede, Peripheral neuropathic pain: a mechanism-related organizing principle based on 
sensory profiles. Pain 158, 261-272 (2017). 
62. I. P. Kleggetveit, B. Namer, R. Schmidt, T. Helas, M. Ruckel, K. Orstavik, M. Schmelz, E. Jorum, 
High spontaneous activity of C-nociceptors in painful polyneuropathy. Pain 153, 2040-2047 
(2012). 
63. J. L. Ochoa, M. Campero, J. Serra, H. Bostock, Hyperexcitable polymodal and insensitive 
nociceptors in painful human neuropathy. Muscle & nerve 32, 459-472 (2005). 
64. H. Bostock, M. Campero, J. Serra, J. L. Ochoa, Temperature-dependent double spikes in C-
nociceptors of neuropathic pain patients. Brain : a journal of neurology 128, 2154-2163 
(2005). 
65. J. Serra, W. R. Duan, C. Locke, R. Sola, W. Liu, W. Nothaft, Effects of a T-type calcium channel 
blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic 
neuropathy: a randomized controlled trial. Pain 156, 2175-2183 (2015). 
66. M. Tsuda, H. Ueno, A. Kataoka, H. Tozaki-Saitoh, K. Inoue, Activation of dorsal horn microglia 
contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein 
kinase signaling. Glia 56, 378-386 (2008). 
67. L. Sorensen, P. J. Siddall, M. I. Trenell, D. K. Yue, Differences in metabolites in pain-
processing brain regions in patients with diabetes and painful neuropathy. Diabetes Care 31, 
980-981 (2008). 
68. D. Selvarajah, I. D. Wilkinson, M. Maxwell, J. Davies, A. Sankar, E. Boland, R. Gandhi, I. 
Tracey, S. Tesfaye, Magnetic resonance neuroimaging study of brain structural differences in 
diabetic peripheral neuropathy. Diabetes Care 37, 1681-1688 (2014). 
27 
 
69. D. Yarnitsky, M. Granot, H. Nahman-Averbuch, M. Khamaisi, Y. Granovsky, Conditioned pain 
modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 153, 1193-1198 
(2012). 
70. S. Noh, N. Kumar, N. Bukhanova, Y. Chen, P. L. Stemkowsi, P. A. Smith, The heart-rate-
reducing agent, ivabradine, reduces mechanical allodynia in a rodent model of neuropathic 
pain. European journal of pain (London, England) 18, 1139-1147 (2014). 
71. R. W. Milne, R. L. Nation, A. A. Somogyi, The disposition of morphine and its 3- and 6-
glucuronide metabolites in humans and animals, and the importance of the metabolites to 
the pharmacological effects of morphine. Drug metabolism reviews 28, 345-472 (1996). 
72. J. S. Borer, J. C. Tardif, Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic 
stable angina pectoris and diabetes mellitus. The American journal of cardiology 105, 29-35 
(2010). 
73. J. J. Cox, F. Reimann, A. K. Nicholas, G. Thornton, E. Roberts, K. Springell, G. Karbani, H. Jafri, 
J. Mannan, Y. Raashid, L. Al-Gazali, H. Hamamy, E. M. Valente, S. Gorman, R. Williams, D. P. 
McHale, J. N. Wood, F. M. Gribble, C. G. Woods, An SCN9A channelopathy causes congenital 
inability to experience pain. Nature 444, 894-898 (2006). 
  
We would like to thank Carl Hobbs, Larissa G. Pinto and Thomas Guegan for assistance with 
experimental procedures and Tamara Buijs for proofreading the manuscript. 
Funding:  
Supported by the Medical Research Council (CT, MR/J013129/1), the BBSRC (SL, BB/J009180/1 and 
BV, BB/L002787/1) and the Wellcome Trust (CT, 099259/Z/12/Z). 
Author contributions:  
CT and PAM planned the study and wrote the manuscript. CT carried out all in vivo experiments, 
immunohistochemistry and biochemistry. SL performed DRG culture and HCN2 electrophysiology 
(Fig. 7). SW and IM carried out cAMP ELISA and HCN2 immunohistochemistry, respectively. BV did 
patch-clamping (fig. S8).  
Competing interests:  
PAM is involved in a drug discovery program, funded by the Wellcome Trust, to develop HCN2-
selective molecules as analgesics. CT, SLV, SW, IM and BV declare no competing interests. 
Data and materials availability: 
28 
 
All data supporting the findings of this study are available within the paper. Transgenic animals are 
available upon request from the corresponding author. 
Table 1: WT mouse usage and percentages that developed diabetes and painful diabetic neuropathy 
 
Injected  
with STZ 
Developed 
diabetes 
Culled  
before 8 weeks 
Pain hypersensitivity 
at 8 weeks 
Cohort 1 18 15/18 (83%) 2 9/13 (69%) 
Cohort 2 18 17/18 (94%) 0 13/17 (76%) 
Cohort 3 20 16/20 (80%) 1 13/15 (87%) 
Cohort 4 20 19/20 (95%) 0 16/19 (84%) 
Total 76 67/76 (88%) 3 51/64 (80%) 
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Figure 1: Ivabradine is analgesic in a mouse model of Type 1 diabetes 
(A) Time course of blood glucose concentrations after a single injection of vehicle (VEH, blue) or STZ 
(red, 150 mg/kg, i.p.) in mice. BL: pre-injection baseline blood glucose. ***p<0.001 vs BL; VEH, n=6 
mice; STZ, n=11 at BL and n=9 at 52 days, due to STZ-induced weight loss over the experimental time 
course (see Table 1).   One-way repeated measurements (RM) ANOVA followed by Student–
Newman–Keuls (SNK) post hoc; ***P<0.001 vs BL; VEH, n=6 mice; STZ, n=11 at BL and n=9 at 52 
days, due to STZ-induced lethality over the experimental time-course. (B) Time course of sensitivity 
to mechanical stimulation, shown as the von Frey force threshold for withdrawal, in VEH or STZ 
treated mice; *P<0.05, *P<0.001 vs baseline; VEH, n=6; STZ, n=18 (BL), n=12 (8 weeks). (C) Time 
course of the thermal withdrawal latency in VEH or STZ treated mice; **P<0.01 vs vehicle; VEH, 
n=12; STZ, n=13 (baseline), n=10 (8 weeks). (D) Time course of sensitivity to mechanical stimulation, 
shown as the von Frey force threshold for withdrawal in control (WT) or diabetic (STZ-injected) mice 
treated with different doses of ivabradine (IVA) or with vehicle.  Dotted lines show time of injection 
of STZ and IVA; *P<0.05 vs saline; #P<0.05 vs post-STZ; +++P<0.001 vs baseline; 10mg/kg, n=8; 
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2.5mg/kg, n=8; 5mg/ml, n=6; saline, n=14 mice. (E) Effect of repeated injection of 5 mg/kg IVA on 
the von Frey force threshold in STZ mice. Dotted lines show the time of STZ (red) and IVA (blue) 
injection. *P<0.05, ***P<0.001 vs saline; ##P<0.01, ###P<0.001 vs post-STZ; +++P<0.001 vs BL; 
n=6/group. (F) Effect of two daily injections of 5 mg/kg IVA for 4 days on the von Frey force 
threshold in STZ mice. Dotted lines show the time of injection of STZ (red) and IVA (blue).  IVA was 
injected twice daily over 4 days, 3 hours before and 3 hours after von Frey threshold testing. 
*P<0.05, *P<0.01 vs saline; ##P<0.01, ###P<0.001 vs post-STZ; +++P<0.001 vs BL; n=6/group. Statistical 
analysis was performed using two-way repeated measures ANOVA followed by Student–Newman–
Keuls post hoc tests. 
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Figure 2: Ivabradine is analgesic in a mouse model of Type 2 diabetes 
(A) Blood glucose concentration in mice heterozygous (db/+, controls) and homozygous (db/db, 
model of type 2 diabetes) for the db mutation. Student’s t-test; ***P<0.001; db/db (n=12 mice), 
db/+ (n=6 mice). (B) Von Frey force threshold in control (db/+) or diabetic (db/db) mice; Student’s t-
test; ***P<0.001; n=6 mice/group. (C) Effect of 5 mg/kg IVA or vehicle i.p. injection on the von Frey 
force threshold in db/db mice. Dotted line shows the von Frey force threshold in control (db/+) mice. 
Two-way ANOVA followed by Bonferroni; ***P<0.001 vs saline, n=14 mice/group except 120 min, 
where n=6 mice/group. 
 
32 
 
 
 
Figure 3: Diabetes-induced C-FOS expression in spinal dorsal horn neurons is reduced by 
ivabradine  
(A) Representative images of the immunohistochemical analysis showing NeuN (left, red) and C-FOS 
(right, green) expression in spinal dorsal horn neurons in WT vehicle, STZ vehicle and STZ+IVA 
injected mice. Inset, higher magnification of dashed rectangles. Scale bars, 50 μm. Arrows indicate 
cells co-expressing NeuN and C-FOS.  (B) Quantification of C-FOS-positive neurons in the three 
different experimental conditions depicted in (A). One-way ANOVA followed by Student–Newman–
Keuls post hoc tests; ***P<0.001; control, n=4; STZ, n=3; STZ+IVA, n=3 mice. 
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Figure 4: HCN2 deletion from nociceptive neurons prevents development of pain and C-FOS 
induction in diabetic mice 
(A) Blood glucose concentration in mice in which HCN2 has been genetically deleted in Nav1.8-
expressing sensory neurons (HCN2 cKO), as well as in their littermates (fHCN2+/+, effectively WT, 
used as control). Two-way repeated measures ANOVA followed by Student–Newman–Keuls post hoc 
test; ***P<0.001 vs BL; P>0.05 for fHCN2 vs HCN2 cKO; HCN2 cKO, n=12; fHCN2, n=20 mice. (B) Time 
course of the von Frey force threshold in fHCN2 and HCN2 cKO mice after STZ injection (indicated by 
dotted line). Two-way repeated measures ANOVA followed by Student–Newman–Keuls post hoc 
test; *P<0.05, ***P<0.001 vs fHCN2, ###P<0.05 vs baseline; HCN2 cKO, n=17 (baseline), n=10 (8 
weeks) mice; fHCN2, n=21 (baseline), n=10 (8 weeks) mice. (C) Representative immunohistochemical 
images showing NeuN (left, red) and C-FOS (right, green) expression in spinal dorsal horn neurons 8 
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weeks after STZ in fHCN2 and HCN2 cKO. The graph on the right shows quantification of C-FOS-
positive neurons in fHCN2 and HCN2 cKO STZ-treated animals. Student’s t-test; ***P<0.001; n=3 
mice per group. Inset, higher magnification of dashed rectangle. Scale bar, 50 μm; arrows show 
neurons co-expressing NeuN and C-FOS. 
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Figure 5: Diabetes decreases intra-epidermal nerve fiber (IENF) density in the skin of the hindpaw 
in mice 
(A)  Representative skin section from a control mouse stained for PGP9.5 (marker of nerve fibers), 
collagen IV (marker of basement membrane separating dermis from epidermis), and DAPI (marker of 
cell nuclei). Merged signal is shown in the far-right panel. Multiple free nerve endings crossing into 
the epidermis are visible in the merged image (arrows). (B) Top, representative 
immunohistochemical images of skin innervation in WT control, WT diabetic (WT STZ), fHCN2+/+ 
(effectively WT) diabetic (fHCN STZ), and Nav1.8-Cre/HCN2 KO (HCN2 cKO) mice. Bottom, 
quantification of IENF density. One-way ANOVA followed by Student–Newman–Keuls; *P<0.05; n=3 
mice per group except HCN2 cKO STZ where n=6. (C) Top, representative immunohistochemical skin 
images showing CGRP, collagen IV, and DAPI staining. Bottom left, quantification of CGRP+ fiber 
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density in control and STZ mice. Student’s t-test; **P<0.01; control, n=6; STZ, n=3 mice. Bottom 
right, correlation of CGRP+ fiber density and threshold for noxious heat in diabetic mice. Pearson’s 
correlation test; **P<0.01; n=6 mice. Scale bars, 40 μm.  
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Figure 6: HCN2 expression in sensory neurons is not regulated by diabetes  
(A) Representative immunohistochemical staining for the pan-neuronal marker β3tubulin (green), 
HCN2 (red), and the merged signal in transverse sections of lumbar DRG from control or diabetic 
(STZ) WT mice. Examples of HCN2-positive neurons are indicated by arrows. Scale bar = 40 μm. (B) 
Left, percentage of HCN2+ neurons in control and STZ mice (Student’s t-test). Middle, distribution of 
HCN2 + neurons amongst DRG size classes (chi-square test). Right, intensity of HCN2 
immunoreactivity as a function of neuronal size (linear regression analysis comparing slopes). 
Control (n=4 mice), STZ (n=4 mice). (C) Representative immunohistochemical staining in transverse 
sections of lumbar DRG for Nav1.8+ (marker of small nociceptive DRG neurons, green), HCN2 (red), 
and the merged signal in WT, HCN2 cKO, and HCN2 gKO.  Examples of Nav1.8+ neurons are indicated 
by arrows. Scale bar, 40 μm.    
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Figure 7: Diabetes does not affect electrical properties of isolated nociceptive neurons  
(A, B) Action potential firing frequency as a function of injected current (0-50 pA) in small DRG 
neurons (<20 m diameter) from STZ (A) and non-diabetic (B) mice (n=5 mice/group), in control 
conditions (control, ◼ n=36; STZ,  n=29) or exposed to 50 M forskolin (control,⚫ n=16; STZ, 
n=16). Only neurons showing a tonic type firing were analyzed (see panel C). Student’s t-test after 
combining the numbers of spikes/s for each neuron at 40 and 50 pA current injection; ***P<0.001 
for (A) and **P<0.01 for (B). (C) Examples of the two firing patterns observed in small DRG neurons 
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after 10 (left) and 50 (right) pA current injection. Cells showing only one spike or transient firing of a 
few spikes after 50 pA current injection were classified as strongly adapting or phasic (upper traces), 
whereas those showing a maintained train of action potentials were classified as tonic (lower 
traces). (D) Proportions of small DRG neurons from STZ and non-diabetic mice, classified as in C, in 
control conditions and after increase in cAMP by forskolin (50 M). Forskolin increased the ratio of 
tonic/phasic firing neurons (control, P=0.043; STZ, P=0.081), with no significant difference between 
the two groups (chi-squared test; P>0.05; cell numbers noted above graphs). (E) Maximum current 
densities in small DRG neurons from STZ and control mice, recorded using a hyperpolarizing voltage 
step from -60 mV to -140 mV for 1.5 seconds, without and with application of 50 µM forskolin. One-
way ANOVA; P>0.05; STZ, n=39; control, n=37 cells. (F) Ih activation curves in small DRG neurons. Left 
panel, curves from STZ mice in the absence (◼, solid line, n=32) or presence (⚫, dotted line, n=15) of 
50 µmol/L forskolin. Right panel, curves from non-diabetic mice without (, solid line, n=23) or with 
(, dashed line, n=16) forskolin. A significant shift to a more depolarized voltage is observed in both 
cases (two-way ANOVA followed by Bonferroni; ***P<0.001) but there is no difference between STZ 
and control mice (two-way ANOVA; P>0.05). 
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Figure 8: Pain in diabetes is associated with increased cAMP in DRG 
(A) Bar graph showing cAMP concentration in lumbar DRG in control (non-diabetic, n=6), STZ 
mice with no mechanical hyperalgesia (‘STZ no pain’, n=5) and STZ mice with mechanical 
pain hypersensitivity (‘STZ pain’, n=4). One-way ANOVA followed by Student–Newman–
Keuls; *P<0.05. (B) Effect of systemic treatment with IVA or different doses of PKA inhibitor 
H-89 on von Frey threshold (P<0.05 IVA vs H-89 at any dose). n=12/group; two-way RM 
ANOVA followed by Student–Newman–Keuls; *P<0.05; **P<0.01, H-89 5 mg/kg or IVA vs 
post-STZ; ##P<0.01; ###P<0.001 IVA vs saline; +++P<0.001 vs BL. 
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Supplementary Information 
 
Materials and methods 
 
Animals 
Experiments on wild-type mice were conducted using adult male C57/BL6 mice (6-8 weeks old at the 
start of experiment, Charles River). For experiments with transgenic mice, we used both male and 
female Nav1.8-Cre/HCN2-/- (conditional knock-out, cKO) and floxed littermate adults (8-24 weeks 
old) backcrossed onto a C57/BL6 genetic background for 6 generations as described in detail 
elsewhere (7). Specificity of HCN2 antibody immunoreactivity was validated using DRG tissue from 
conditional as well as global KO (gKO) mice (7).   
All mice were housed in groups of five with standard rodent food and water ad libitum, on a 12 hr 
light/dark cycle. All animals were allowed to acclimatize to their environment for at least 1 week 
before study. All experiments were compliant with institutional guidelines and the Committee for 
Research and Ethical Issues of IASP, as well as in strict accordance with protocols established by the 
Animal Models of Diabetic Complications Consortium (AMDCC) and the Home Office (UK) 
regulations and the Animals (Scientific Procedures) Act 1986. 
 
Diabetes models 
For induction of Type 1 diabetes, mice were fasted for 4 hrs and given a single injection of 150mg/kg 
streptozotocin (STZ; Sigma S0130, diluted in 0.1μM sodium citrate buffer, pH 4.5, injected i.p.). 
Vehicle-treated mice received an injection of sodium citrate buffer. All injection volumes were 10 
ml/kg body weight. Mice were provided with 10% sucrose drinking solution in place of water for 48 
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hrs following STZ treatment, to avoid sudden hypoglycaemia. Before and after diabetes induction, 
blood-glucose levels in tail vein blood were determined with an AlphaTRAK 2 meter (Abbott) to 
confirm hyperglycemia (defined as blood-glucose > 16.6mmol/L). For study of Type 2 diabetes, we 
used 12-18 week old male BKS.Cg-Dock7m +/+ Leprdb/J mice (Charles River, stock number 000642). 
The homozygous (Leprdb/ Leprdb, or db/db) mice were used as a model of Type 2 diabetes, while 
heterozygous mice (Leprdb/+, or db/+) served as non-diabetic controls. Hyperglycemia in db/db mice 
was confirmed using a glucose meter and tail blood, as described above.  
Animal well-being was carefully monitored and diabetic mice that lost more than 20% weight at any 
point of the study were culled by a schedule 1 method. For this reason, in some of the experiments 
conducted over 8 weeks the n numbers declined during the course of the study, as reported in 
Figure legends. Mice that did not become hyperglycemic (Type I, <12%; Type II, none, see criteria 
above) were excluded from the diabetic group. For characterisation of pain in diabetes (Fig. 1A-C, 
Fig. 2B, Fig. 4) we included all mice that developed hyperglycemia. Approximately 70-90% of Type I 
and 50-60% of Type II diabetes mice developed some degree of pain hypersensitivity, and when 
testing analgesic treatments in behavioural experiments (Fig. 1D-F, Fig. 2C, Fig. 3), performing 
immunohistological analysis (Fig. 3, Fig. 5, Fig. 6) and patch-clamping (Fig. 7) we included only 
diabetic mice that developed significant pain (mechanical thresholds <3.5g at time of testing, 
corresponding to at least ~20% decrease compared to pre-STZ baseline (Type I) or control 
littermates (Type II)). For ELISA quantification of cAMP levels (Fig. 8) we used DRG from diabetic pain 
responders (‘STZ pain’, mechanical thresholds <3.5g) and non-responders (‘STZ no pain’, mechanical 
thresholds not significantly different from baseline (P>0.05)).      
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Behavioural testing 
Drug treatment 
Ivabradine (Sigma SML0281) was diluted to the desired concentration in vehicle (DPBS, Gibco) and 
injected intraperitoneally (i.p.) at a volume of 10 ml/kg body weight. Ivabradine was delivered either 
as a single injection, as 3 injections over 6 hrs, or twice daily (3hrs before and 3hrs after pain testing) 
for 4 consecutive days, as described in the Results section. H-89 (Tocris) was diluted in water to 
make a 10mg/ml stock and further dilutions were made in DBPS. H-89 or vehicle (DPBS) was injected 
intraperitoneally (i.p.) at a volume of 10 ml/kg body weight as described in Results. Prostaglandin E2 
(PGE2, Sigma P5640) was diluted to 10 mg/ml in ethanol and further diluted to 3μg/ml in DPBS. A 
total of 10μl of this solution (30ng in total) was delivered into the mouse paw. 
Mechanical pain  
Mechanical sensitivity was assessed using a dynamic plantar aesthesiometer (Ugo Basile, Varese, 
Italy) as previously described (70). Briefly, animals were placed in a ventilated plexiglass chamber 
upon an elevated aluminium screen surface with 1cm mesh openings and allowed to acclimatize to 
their environment. Once exploratory behaviour had ceased, an actuator filament (0.5mm diameter) 
under computer control delivered a 10sec ramp of increasing force (0 to 5 g) to the plantar surface 
of the hindpaw until the animal withdrew the paw. Paw withdrawal thresholds were averaged over 
at least 5 measurements with 5 min intervals in between. To monitor mechanical hypersensitivity in 
painful diabetic neuropathy, paw withdrawal thresholds were measured before diabetes induction 
with STZ and bi-weekly thereafter for 8 weeks. For assessment of the effect of acute ivabradine 
injections, pain thresholds were acquired before and 30, 60 and 120 min after drug delivery, while 
following the chronic ivabradine regime, pain thresholds were measured daily for 4 consecutive 
days, midway in time between injections.  
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Heat pain  
Thermal sensitivity was assessed with the Hargreaves method, as previously described(71). Briefly, 
each mouse was placed into a ventilated plexiglass cage on an elevated glass floor. A calibrated 
radiant light source (Ugo Basile) delivered a constant thermal stimulus (heating rate 0.5°C/sec) to 
the hindpaw and the latency to withdrawal was recorded. Withdrawal thresholds were averaged 
from at least 5 consecutive tests, with a minimum of 5 minutes in between measurements. A 25 sec 
cut-off was imposed to prevent tissue damage. Heat withdrawal thresholds were measured before 
diabetes induction with STZ and bi-weekly thereafter for 8 weeks. 
Pulse oximetry 
Mice were fitted with a collar transducer clip connected to a MouseOx pulse oximetry system (Starr 
Life Sciences, USA) and habituated in individual plexiglass chambers for at least an hour before 
monitoring commenced. Following this, baseline values for heart rate, oxygen saturation, breath 
rate and pulse detention were recorded by the oximetry software. After intraperitoneal injection of 
ivabradine or saline solution, the mouse was returned to the chamber and the same parameters 
were recorded at 30, 60 and 120 minutes post-injection. Average values were calculated from three 
individual measurements. 
 
Electrophysiology  
DRG neuron culture 
At the endpoint of behavioural testing, cultures of DRG neurons from diabetic and control mice were 
prepared. Briefly, 8-24 week-old mice underwent cervical dislocation and decapitation, and the DRG 
were exposed via laminectomy. DRG from all spinal levels were collected and placed in cold 
Dulbecco’s modified Eagle’s medium (DMEM, Gibco) containing 25mM glucose. After axon trimming, 
DRG were incubated for 1 hour in collagenase-supplemented DMEM at 37C (2mg/ml, 
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Worthington). Following collagenase removal, DRG neurons were mechanically dissociated by 
manual trituration and plated into 13mm culture dishes pre-coated with a mixture of poly-l-lysine 
(100μg/ml) and laminin (20μg/ml) in DMEM. Electrophysiological recordings were performed at 
room temperature (22°C) 3-10 hrs after plating. 
Solutions 
For manual patch-clamp experiments neurons were transferred for a maximum of 20 mins to an 
extracellular solution containing (in mmol/L): 140 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, 5 glucose 
and 10 D-Mannitol (pH adjusted to 7.3 and osmolality to 308 mOsm/L). To make sure the 
concentration of glucose in the extracellular solution did not affect properties of diabetic neurons 
during patch-clamping, we also performed control experiments using either 5mM or 25mM glucose 
in the extracellular solution, in which D-mannitol was adjusted to maintain equiosmolarity (see Fig. 
S7). The intracellular solution contained (in mmol/L): 140 KCl, 1.6 MgCl2, 2.5 MgATP, 0.5 NaGTP, 2 
EGTA and 10 HEPES (pH adjusted to 7.25 and osmolality to 290 mOsm/L). To stimulate cAMP 
production, 50 μmol/L forskolin (prepared from 100mM stock in DMSO) was applied in extracellular 
solution and was prepared on the day of the experiment. All reagents were purchased from Sigma-
Aldrich. 
Whole-cell patch-clamp recordings 
Whole-cell patch-clamp recordings were performed using an Axiopatch 200B patch-clamp amplifier. 
Borosilicate patch-clamp pipettes (Science Products GmbH) were pulled using a P-97 horizontal 
micropipette puller (Sutter Instruments). Before use, all pipettes were fire polished with a Narishige 
MF-900 microforge giving a final resistance ranging between 2.5 and 3.5 M. Pipette offset was 
corrected before approaching the cell. Once a giga-seal was obtained between the pipette and the 
cell, capacitative transients were cancelled before achieving the whole-cell configuration. Series 
resistance was compensated by 40-60%. Cells were held at -60 mV in the voltage-clamp 
configuration before applying the voltage pulse protocol. When working in current-clamp mode, the 
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I-Clamp fast mode without steady current injection was used. Whole-cell current and voltage 
recordings were sampled at 20 KHz and low-pass Bessel filtered at 2 KHz. Data was acquired using 
Axon pCLAMP software version 10.4 and was analysed offline with Clampfit 10 (Molecular Devices, 
LLC). Recordings were made from neurons either in control conditions or exposed to forskolin for 
between 5-45 mins.   
To determine the voltage-dependence of activation of Ih currents in DRG neurons in the presence or 
absence of forskolin, the midpoint activation voltage (V½) was calculated from tail currents recorded 
after the application of a 1.5 sec long voltage sweep to -140 mV, following the application of a family 
of pre-pulse voltage sweeps ranging from -140 to -40 mV with a 20 mV increase between sweeps 
(1.5 sec long). From these currents both the maximal current density and V½ were calculated. To 
calculate V½, activation-voltage plots were fitted using a Boltzmann equation: 
 
 
Where Vm is the membrane potential of the pre-pulse, V½ is the midpoint activation voltage, k is the 
slope factor, It is the current amplitude of the tail current recorded at -140 mV for a given pre-pulse 
and It (max) is the maximum current amplitude of the tail current.  
 
 
Immunohistochemistry (IHC) 
Mice were anaesthetized and transcardially perfused with 4% paraformaldehyde in 0.1M phosphate 
buffer (pH 7.4) and tissue was dissected and post-fixed at 4°C (DRG, 5 min; nerve and skin, 2 hrs; 
spinal cord, 24 hrs). Tissue was then equilibrated in 20% sucrose in PBS at 4°C for 24-72 hrs, 
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embedded in O.C.T. (Optimum Cutting Temperature) compound and rapidly frozen on liquid N2. A 
cryostat was used to cut sections at the required thickness (DRG, 10 μm; skin, 14 μm; spinal cord, 20 
μm; nerve, 20 μm) and 5-10 sections were thaw-mounted onto Superfrost Plus glass slides (VWR). 
Prior to antibody staining, non-specific immunoreactivity was blocked by 1 hr incubation in PBS 
supplemented with 0.1% Triton X-100 (Sigma), 4% donkey serum (Jackson ImmunoResearch Labs) 
and 0.5% skimmed milk (Tesco).  
Slides were washed in PBS and incubated overnight at 4°C with the primary antibody solution (PBS 
supplemented with 0.3% Triton X-100, 2% BSA (Sigma), 4% normal donkey serum and 4% normal 
goat serum (Jackson ImmunoResearch)). Primary antibodies used were rabbit anti-HCN1 (1:500, 
Alomone #APC-056), rabbit anti-HCN2 (1:1000, Alomone #APC-030), rat anti-HCN3 (1:500, TLL6C5, 
Thermo Scientific), rabbit anti-HCN4 (1:500, Alomone #APC-052), mouse anti-NeuN (1:1000, Abcam 
#ab104224), chicken anti-β3tubulin (1:1000, Abcam #ab41489), mouse anti-Nav1.8 (1:1000, 
Neuromab N134/12), rabbit anti-c-fos (1:1000, Cell Signalling #2250), rabbit anti-PGP9.5 (1:2000, 
Ultraclone #RA95101), mouse anti-PGP9.5 (1:1000, Abcam ab8189), rabbit anti-CGRP (1:2000, Sigma 
C8198), goat anti-collagen IV (1:400, Millipore #AB769). When using ab8189 to stain PGP9.5 in the 
skin, antigen retrieval (30 min at 80°C in 10mM sodium citrate buffer, pH 6.0) was performed prior 
to incubation with the primary antibodies. The next day slides were washed and incubated for 2 hrs 
with the appropriate secondary antibodies; donkey anti-mouse IgG-conjugated Alexa Fluor 594, goat 
anti-chicken IgG-conjugated Alexa Fluor 546, donkey anti-rat IgG-conjugated Alexa Fluor 647, donkey 
anti-rabbit IgG-conjugated Alexa Fluor 488, donkey anti-goat-conjugated Alexa Fluor 594 (all 1:1000, 
Invitrogen). For skin IHC, DAPI staining was performed concurrently with the secondary antibody 
incubation. After a final wash, slides were mounted with FluorSave mounting medium (Calbiochem). 
Antibody specificity for HCN2 was confirmed using tissue from KO mice while validation information 
for other primary antibodies used is available on the manufacturer’s website. 
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Image analysis 
Antibody staining was visualised under a fluorescence microscope (Zeiss) and images were acquired 
using a digital camera and Axiovision software. For each experiment, tissue staining and imaging of 
all slides was performed at the same time to minimise variability and the same exposure settings 
were used for image acquisition across all slides. Analysis of immunofluorescence was carried out 
with ImageJ software (http://rsbweb.nih.gov/ij/). For each image, 3 background intensity 
measurements were taken and mean intensity of background (BG) as well as its standard deviation 
(SD) were calculated; a cell was only considered positive when its immunoreactivity intensity was 
higher than 2xBG + 6SD. These objective criteria correlated well with subjective criteria of positively 
labelled cells. Measurements were conducted using a 20x objective from at least 5 sections per DRG 
(>200 cell profiles/animal). Measurement of cell diameter was only carried out on cells that had a 
clearly visible nucleus.  
For quantification of intra-epidermal nerve fiber (IENF) density, z-stack images were acquired from 
at least 6 sections per animal. The number of PGP9.5-positive fibers crossing the epidermis-dermis 
boundary (basal membrane) in each image was counted according to the European Federation of 
Neurological Societies (EFNS) guidelines (72). PGP9.5 is also expressed by Langerhans cells (LC) in the 
epidermis, and the processes of these cells can occasionally resemble IENFs. These LC processes 
were excluded from analysis of IENF density based on their morphology (i.e. they lack the ‘beaded’ 
appearance of nerve fibers), as well as their association with a positively stained cell body. IENF 
density was calculated by dividing the number of IENF with the total length of the basal membrane. 
Quantification of c-fos activation in sections of spinal cord was performed by counting the number of 
c-fos immunoreactive neurons in the dorsal horn in at least 6 sections per animal. For quantification 
of HCN2 staining in sciatic nerve, we measured the mean density of immunoreactive signal in 
defined Regions Of Interest (ROIs, at least 8 per animal) placed on top of the nerve using ImageJ.  
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cAMP ELISA 
Cyclic adenosine monophosphate (cAMP) was quantified using a commercial ELISA kit (Enzo Life 
Sciences). Briefly, five DRG (L1-L5) per mouse were rapidly dissected and immediately frozen in dry 
ice (within 5min of mouse death). Samples were ground using a small teflon pestle over liquid N2, 
followed by vortexing in 250μl of lysis buffer (1% Triton X-100 supplemented with 0.1M HCl to stop 
endogenous phosphodiesterase activity). Samples were centrifuged at 600g to pellet the debris and 
supernatants were collected and run in duplicate on the ELISA plate, according to the 
manufacturer’s protocol. Calculated cAMP levels were normalised to total protein content, 
measured using the Pierce 660 nm Protein Assay Kit (Thermo Scientific). 
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Figure S1: Ivabradine does not affect heat thresholds in naïve or diabetic mice 
Ivabradine (5mg/kg i.p.) did not alter heat pain thresholds in control mice (P>0.05 vs vehicle). 
Withdrawal thresholds to heat stimulation were higher in diabetic mice (8 weeks post-STZ) at 
baseline (P<0.05), and were also not significantly affected by ivabradine when compared to a vehicle 
injection (P>0.05). Two-way RM ANOVA with SNK post-hoc; *P<0.05 for STZ + IVA vs WT + IVA; 
#P<0.05 for STZ + veh vs WT + veh; n=6/group. 
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Figure S2: Effect of ivabradine on cardiac parameters in vivo 
(A) Ivabradine administration (5mg/kg, i.p.) resulted in a significant drop in basal heart rate of 
control mice from 653.2 ± 21.8 beats per minute (bpm) at baseline to 462.3 ± 13.7 bpm at 30’ (a 
29.2% reduction), which was also significantly different from vehicle treatment (P=0.006). The same 
effect was observed in STZ mice (from 647.1 ± 16.9 to 545.1 ± 15.7 bpm, P=0.009 vs vehicle). 
Interestingly the magnitude of the reduction was smaller in STZ mice (15.8% reduction compared to 
baseline), however this was not significantly different to the effect on control mice (P=0.173). (B) 
Ivabradine treatment also reduced breath rate in both control (P=0.007 vs vehicle) and diabetic 
(P=0.014 vs vehicle) mice. (C) Both diabetic and non-diabetic mice showed similar values for oxygen 
saturation, and no change was detected following injection of ivabradine. (D) Pulse distention did 
not differ between control and diabetic groups and remained unaltered after administration of 
ivabradine. Cardiac etc parameters measured with pulse oximetry (MouseOx) in freely moving 
subjects. Diabetic mice 8 weeks post-STZ. Ivabradine and vehicle injected i.p. at time zero. Two-way 
ANOVA with SNK; *P<0.05, **P<0.01 and ***P<0.001 compared to vehicle; CTRL, n=6/group; STZ, 
n=5/group. 
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Figure S3: Regulation of axonal HCN2 expression by diabetes  
(A) Quantification of HCN2 immunoreactivity in sciatic nerve showed similar levels of expression 
before and after induction of diabetes. Student’s t-test; P>0.05; n=4 mice/group. (B) No HCN2 signal 
could be detected in epidermal nerve fibers in the skin. Scale bars=40μm. 
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Figure S4: HCN1 expression in control and diabetic DRG neurons  
Immunohistochemistry for HCN1 (red) on transverse sections of lumbar DRG from control or diabetic 
mice (8 weeks post-STZ). Sections were co-stained with β3tubulin (green) to label all sensory 
neurons. HCN1 was pre-dominantly localised in medium-large neurons, with no difference between 
control (42.2 ± 1.6% of all neurons) and diabetic (42.4 ± 3.7%) conditions (left graph; Student’s t-test, 
P=0.964). Diabetes also did not affect HCN1 distribution in different DRG classes (middle graph; chi-
square test, P=0.477), mean intensity of HCN1(+) neurons overall (right graph, 3.1 ± 0.3 vs 3.4 ± 0.2 
A.U.; Student’s t-test, P=0.433) or amongst different sizes (comparison of line slopes, P=0.206). 
Control (n=4 mice), diabetic (n=4 mice). Scale bar = 40 μm. 
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Figure S5: HCN3 expression in diabetic DRG neurons  
Immunohistochemistry for HCN3 (red) on transverse sections of lumbar DRG from control or diabetic 
mice (8 weeks post-STZ) also labelled for β3tubulin (green). The HCN3 isoform was detected in a 
mixture of neurons of all sizes and diabetes did not affect overall expression levels when examining 
percentage of positive neurons (left graph, 44.5 ± 4.3% vs 45.0 ± 5.2%; Student’s t-test, P=0.952), 
despite a small increase in the small neuron sub-population (from 36.2% to 51.0% of all HCN3-
positive; middle; chi-square test, P=0.0007). Nevertheless, there was no diabetes effect on mean 
intensity of HCN3 staining across all neurons (right graph, 3.2 ± 0.1 vs 3.2 ± 0.1 A.U.; Student’s t-test, 
P=0.775) or within different sizes (line slope comparison, P=0.120). Control (n=4 mice), diabetic (n=4 
mice). Scale bar = 40 μm. 
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Figure S6: HCN4 expression in diabetic DRG neurons  
Immunohistochemistry for HCN4 (red) on transverse sections of lumbar DRG from control or diabetic 
mice (8 weeks post-STZ) also labelled for β3tubulin (green). HCN4 was found mainly in medium-large 
neurons, with similar levels of expression in control and diabetic conditions (left graph, 32.4 ± 2.0% 
vs 29.0 ± 4.9%; Student’s t-test, P= 0.55) and no change in the channel distribution amongst classes 
(middle graph; chi-square test, P=0.415). Staining intensity (right graph) after diabetes did not differ 
from control when comparing all neurons (2.8 ± 0.2 vs 2.8 ± 0.2 A.U.; Student’s t-test, P= 0.702) or 
distinct subclasses (line slope comparison, P=0.287). Control (n=4 mice), diabetic (n=4 mice). Scale 
bar = 40 μm. 
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Figure S7: Effect of high glucose on properties of Ih in nociceptive neurons 
(A, B) Ih activation curves in small DRG neurons from diabetic and non-diabetic mice in presence of 
5mM or 25mM glucose (n=15 cells/group). Two-way ANOVA; P>0.05. See Methods for details of 
determination of Ih activation curves. (C) Maximum current densities in small DRG neurons from 
diabetic and non-diabetic mice, recorded using a hyperpolarizing voltage step from -60mV to -140 
mV for 1.5 seconds, in the presence of 5mM or 25mM glucose. One-way ANOVA; P>0.05; n=15 
cells/group. 
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Figure S8: Systemic H-89 treatment reduces PGE2-induced inflammatory pain in naïve mice 
WT mice were systemically treated with the PKA inhibitor H-89 (i.p.) prior to induction of 
inflammatory pain via intraplantar injection of PGE2. H-89 treatment did not affect acute pain 
thresholds, however it caused analgesia following PGE2 sensitisation, especially at higher doses 
(*P<0.05 vs vehicle, 2W RM ANOVA; n=6/group except 20mg/kg where n=5).  
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Figure S9: c-fos induction in the spinal cord 2hrs after intraplantar CFA injection  
Expression of c-fos induced following injection of CFA, a strong algogenic stimulus (113.2 ± 12.4  c-
fos positive neurons per section in laminae I-II), was significantly greater than observed in diabetic 
mice (26 ± 2.6 c-fos positive neurons per section in laminae I-II, see Fig 3, P=0.002, Student’s t-test). 
Scale bar = 200μm.  
 
 
 
